Beijing Cancer Hospital, Department of Breast Oncology, Chief Physician, Associate Professor. Specialty: Comprehensive treatment of breast cancer including chemotherapy, endocrine therapy, targeted therapy, and immunotherapy. Advantages: Extensive clinical experience in the comprehensive management and management of adverse reactions for recurrent, drug-resistant, refractory cases, HER2-positive, triple-negative breast cancer, as well as metastases to the liver, brain, lungs, bones, chest wall, pleural effusion, and pericardial effusion. Research Direction: Molecular precision targeted therapy for breast cancer. Publications Shao B, Gao YR. Immunosuppressive therapy for myelodysplastic syndrome. Medical Review, 2005, 11(5):398-400. Shao B, Zhou Z, Gao YR. Treatment and prognosis analysis of acute myeloid leukemia in very elderly patients. Practical Geriatrics, 2006, 12(1): 23-26. Shao B, Qin YW, Gao YR. Clinical characteristics of acute myeloid leukemia in elderly patients. Chinese Journal of Gerontology, 2006, 6(26):834-836. Shao B, Gao YR, Wang C. Prognostic factors in elderly acute myeloid leukemia. Cancer, 2006, 25(8): 1007-1012. Shao B, Gao YR, Wang C. Individualized treatment of acute myeloid leukemia in elderly patients. Journal of Clinical Hematology, 2006, 19(6):323-326. Shao B, Gao YR, Wang C. Clinical study of CRP in infections of malignant hematological diseases. Chinese Journal of Nosocomiology, 2006, 19(20):2697-2699. Shao B, Yu J, Ren J. Efficacy and influencing factors of docetaxel combined with recombinant human granulocyte colony-stimulating factor for mobilizing peripheral blood stem cells in breast cancer patients. Cancer Prevention and Treatment Research, 2011, 38(6):666-670. Shao B, Yu J, Di LJ, et al. Clinical characteristics and prognostic factor analysis of malignant pleural effusion in breast cancer. Cancer Prevention and Treatment Research, 2013, 40(4):381-387. Shao B, Yu J, Zhu YL, et al. Clinical study of high-dose chemotherapy with paclitaxel and thiotepa as adjuvant therapy in high-risk breast cancer. Cancer Prevention and Treatment Research, 2013, 33(4):334-338. Shao B, Zhang J, Lyu M, et al. Quality of life study in advanced breast cancer patients receiving high-dose chemotherapy with autologous peripheral blood hematopoietic stem cell support. Cancer Prevention and Treatment Research, 2015, 42(2):145-149. Shao B, Song YQ, Zhu J. Dose-adjusted EPOCH-R regimen for primary mediastinal large B-cell lymphoma. Evidence-Based Medicine, 2014, 4(2):87-88. Shao B, Li HP*, Zhu J, et al. Relationship between plasma miRNA expression levels and chemotherapy efficacy and prognosis in patients with recurrent metastatic breast cancer. Cancer Progress, 2015, 13(2):106-113. Shao B, Li HP*, Di LJ, et al. Predictive and prognostic value of peripheral blood lymphocyte subset monitoring in recurrent metastatic breast cancer. Journal of Peking University (Medical Edition), 2016, 16(2):167-172. Shao B, Li HP*, Di LJ, et al. Efficacy and prognostic factors of docetaxel monotherapy versus combination regimens as first-line treatment for metastatic breast cancer. Tumor, 2016, 36(6):683-691. Liu XR#, Shao B#, Peng JX#, et al. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients. Breast, 2017, 32: 119-125. Bin Shao#, Zhihua Tian#, Huirong Ding#, et al. Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer. Int J Clin Exp Pathol 2018;11(2):650-663. Bin Shao, Li CW, Lim SO, et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Am J Cancer Res. 2018 Sep 1;8(9):1837-1846. Bin Shao*, Guohong Song*, Huiping Li, et al. Combination versus Sequential Paclitaxel plus Gemcitabine as First-line Chemotherapy for Women with Metastatic Breast Cancer: A Prospective Randomized Phase II Study. JBUON 2018; 23(6): 1583-1590. Bin Shao, Jinrong Qu, et al. Clinical outcomes with first-line chemotherapy versus endocrine therapy for adjuvant endocrine therapy-resistant metastatic breast cancer. Translational Cancer Research. 2018; 7(3):676-685. Shao B, Wang X, Zhang L, et al. Plasma microRNAs Predict Chemoresistance in Patients with Metastatic Breast Cancer. Technol Cancer Res Treat. 2019 Jan 1; 18:1533033819828709. Gui X, Li H, Song G, Shao B, Jiang H. Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report. Medicine (Baltimore). 2018 Nov; 97(48): e13410. Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, Chan LC, Yang Y, Hsu JL, Lai YJ, Hung MC. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res. 2018 Jul 1; 8(7):1307-1316. Liu X, Ran R, Shao B, Rugo HS, Yang Y, Hu Z, Wei Z, Wan F, Kong W, Song G, Jiang H, Liang X, Zhang R, Yan Y, Xu G, Li H. Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chin J Cancer Res. 2018 Jun; 30(3):315-326. Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun. 2018 Apr 24; 9(1):1614. Peng J, Zhao Q, Zheng W, Li W, Li P, Zhu L, Liu X, Shao B, Li H, Wang C, Yang Y. Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells. ACS Appl Mater Interfaces. 2017 Jun 7; 9(22):18423-18428. Liu X, Li H, Shao B, Wu J, Kong W, Song G, Jiang H, Wang J, Wan F. Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Med. 2017 Mar; 6(3):547-554. Li H, Shao B, Yan Y, Song G, Liu X, Wang J, Liang X. Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. Chin J Cancer Res. 2016 Jun; 28(3):330-8. Education and Work Experience: 1997.9 - 2003.7 Bachelor's Degree, Six-Year English Program, Shandong Medical University 2003.9 - 2006.7 Master's Degree, Internal Medicine, Fudan University 2012.9 - 2015.7 Doctorate, Peking University Health Science Center 2017.5 - 2018.7 Visiting Scholar, M.D. Anderson Cancer Center, USA During the visiting period, research focused on optimizing targeted and immunotherapy for breast cancer, achieving the latest international research results. After returning to China, continued research on how to better integrate traditional chemotherapy and endocrine therapy with targeted therapy and immunotherapy. Currently, 14 papers have been published in core journals. Participated in 1 sub-project of the 973 Program, 1 National Natural Science Foundation project, 1 Beijing Natural Science Foundation project, and multiple international multi-center clinical trials. Professional Affiliations: Beijing Cancer Hospital, Department of Breast Oncology, Chief Physician, Associate Professor. Member, Beijing Breast Disease Prevention and Treatment Society Youth Committee Member, Breast Cancer Branch, Beijing Cancer Prevention and Treatment Society Committee Member, Youth Group of Breast Oncology, Chinese Medical Association Committee Member, Precision Targeted Diagnosis and Treatment Committee, Beijing Cancer Prevention and Treatment Association Deputy Director, Youth Committee of Integrated Breast Cancer Prevention and Treatment, Chinese Association for the Promotion of Integrated Prevention and Treatment of Chronic Diseases Youth Committee Member, Breast Disease Branch, Beijing Medical Association Committee Member, Breast Disease Branch, China International Exchange and Promotive Association for Medical and Health Care Review Expert, "Cancer Progress" Journal.